Legend Innovation Life Science Fund, LLC and Accelero Biostructures today announced a strategic…
Legend Innovation Life Science Fund, LLC (“Legend”) and Provo Real Estate Enterprises, LLC…
About us
Legend Innovation Life Science Fund is focused on investing in life science breakthrough companies and building scalable Biotech real estate projects in the United States and South Korea.
We envision a world where today’s most daunting medical challenges are met with cutting-edge therapies that not only extend life but also enhance its quality. We believe that the key to unlocking this future lies in the innovative potential of biotech companies. By providing these innovators with the resources and strategic guidance they need, we aim to transform the landscape of global healthcare.
Latest News
Leadership
Dr. Syngbum (Ben) Kim, DDS, MS
Principal Manager (Founder)
Dr. Syngbum Kim has served as President of the Yale Alumni Association in New York City. He has a Bachelor of Science in Physics from Seoul National University and is a Yale Fellow with a Master of Science in Engineering and Applied Physics. His groundbreaking achievements in the initial research for the active ingredients in Sensodyne are well known. He has been a member of the clinical faculty of the Columbia School of Dental and Oral Surgery. Dr. Kim has decades of investing experience, real estate expertise, and hedge fund experience and is known by the investment community in both New York and South Korea.
David Horn, MD, F.A.C.P., F.I.D.S.A.
Manager (Co-Founder)
Dr. Horn is currently the CEO and Founder of Mid-Atlantic BioTherapeutics, Inc. Dr. Horn brings over 30 years of research & clinical expertise in numerous therapeutic areas. He has held senior positions at Bristol-Myers Squibb, Merck, Thomas Jefferson University, and continues to serve as a well-respected Industry Consultant. David is a board-certified physician in internal medicine and infectious diseases, and he is an expert in clinical development and medical affairs. Dr. Horn completed his fellowship training in infectious diseases at Brown University, Providence, RI. He is also a fellow of the American College of Physicians and a fellow of the Infectious Diseases Society of America.
Jonathan Lee
Manager (Co-Founder)
Jonathan Lee has a well-established network of contacts within the Korean business community as well as extensive experience in the business sector that will be utilized by the Fund to provide valuable support to bio incubator companies in Korea, which is an important feature of the development and investment approach of the Fund. Mr. Lee is also proficient in establishing efficient management structures to oversee numerous corporations relocating to Korea and has the capability to manage multiple companies that are planning to relocate to Korea in the near future (2-3 years) which is also an important feature of the development and investment approach of the Fund.
Why Biotech?
Investing in biotech right now presents a compelling opportunity driven by several factors converging in the industry. Biotechnology has reached a pivotal moment where scientific advancements, technological innovations, and societal needs are aligning to create unprecedented opportunities for transformative therapies. Here’s why it’s an excellent time to invest in biotech,…
Our Investment Strategy
At the heart of our investment strategy lies a commitment to identifying and supporting biotech companies with the highest potential for transformative impact. We meticulously select companies engaged in groundbreaking research and equipped with robust pipelines that are poised to deliver innovative therapies to the market. Our approach is not…
Why Invest With Us?
Investing with us offers a unique opportunity to be part of a dynamic and forward-thinking life sciences fund that is deeply rooted in expertise, strategic alliances, and a clear path to high growth. Here’s why partnering with us is a compelling choice for investors looking to maximize returns while contributing…